Basic Information
| LncRNA/CircRNA Name | TP73-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000227372 |
| Refseq | NR_033708 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | CC cells (SiHa, HeLa, C-33A, and Caski) and human normal cervical cell (End1/E6E7) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA TP73-AS1 has been found to promote cancer progressions in various cancers. It is upregulated in cervical cancer cells. The proliferation and migration ability of cervical cancer cells can also be boosted by TP73-AS1 in return. Meanwhile, miRNA-329-3p is downregulated in cervical cancer cells and could bind with both TP73-AS1 and ADP Ribosylation Factor 1 (ARF1). TP73-AS1 inhibited miR-329-3p expression while miR-329-3p inhibited ARF1 expression. More importantly, TP73-AS1 can positively regulate ARF1 expression. |
| Pubmed ID | 31232491 |
| Year | 2019 |
| Title | LncRNA TP73-AS1 is a novel regulator in cervical cancer via miR-329-3p/ARF1 axis |
External Links
| Links for TP73-AS1 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |